MYCN and prostate cancer: However, the metastatic brain NEPC lesion had a significant enrichment of E2F and MYC targets, which are transcriptional profiles that reflect altered proliferation (E2F)25 or possibly drive neuroendocrine differentiation in prostate cancer (MYCN)26.